Oramed Pharmaceuticals Inc. (ORMP.TA)
Oramed Pharmaceuticals Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in New York, NY, US. The stock last traded at $1303.00, up 1.32% on the session, giving a market capitalisation of $533.3M. Its beta of 1.16 implies it has historically moved more than the broad market.
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
Oramed Pharmaceuticals Inc. is most often compared with the following Healthcare names: